D-1436-2014 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-1436-2014 was initiated by Teva Pharmaceuticals USA on Jun 17, 2014 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification impurity test results. The recall status is terminated (terminated Mar 9, 2015). Affected quantity: 1104 blister packs.

Recall details

Product Type
Drugs
Report Date
Jul 23, 2014
Initiation Date
Jun 17, 2014
Termination Date
Mar 9, 2015
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1104 blister packs

Product description

Apri (desogestrel and ethinyl estradiol tablets USP), 0.15 mg/0.03 mg, 6 Cyclic dispensers X 28 tablets, Rx only, Teva Pharmaceuticals, Sellersville, PA. NDC 0555-9043-58

Reason for recall

Failed Impurities/Degradation Specifications: out of specification impurity test results.

Distribution pattern

Nationwide

Code information

Lot 3805324A Exp. 11/14

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1436-2014
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1436-2014. Report a data issue: hello@regdatalab.com.